Abstract
While most newly-diagnosed prostate cancers are well-differentiated tumors that have high probability of cure, there is a subset of patients that present with aggressive malignancies that have significant potential for recurrence and metastasis. Single-modality treatment approaches have demonstrated relatively high failure rates, and multimodality therapy (radiation therapy and hormonal ablation therapy) has become standard of care for these patients. These treatments are not without toxicity, and a significant percentage of patients will become refractory to hormonal therapy. Historically, radiation therapy of prostate cancer was associated with significant genitourinary and gastrointestinal morbidity. With advances in radiation therapy techniques and delivery, the potential for safe dose-escalation has emerged. Further, there is an opportunity for chemotherapeutic agents to play an important syngergistic role in radiosensitizing the tumor cells at the primary site while also addressing micrometastatic disease. Concurrent chemoradiation therapy has become standard treatment for many types of locally advanced tumors, including lung, cervical, esophageal, rectal, and anal malignancies. We present a review of clinical trials examining the role of chemoradiation therapy in high-risk prostate cancer.
Keywords: Cancer, chemotherapy, concurrent, high-risk, prostate, radiotherapy, Three-Dimensional Conformal Radiotherapy (3DCRT), Image-Guided Radiation Therapy (IGRT), Estramustine phosphate, depolymerization, plasma testosterone levels, Vinblastine, vinca alkaloid, tubulin, T4 prostatic adenocarcinoma, DOCETAXEL, cytotoxic anti-microtubule agent, PACLITAXEL, IMRT
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
16